As federal efforts to address prescription drug costs intensify, this three-part blog series addresses misleading claims or confusion about Medicaid, its highly effective drug rebate program and overall drug pricing issues in the hopes of better informing the debate moving forward. Part II | Part III In response to federal Medicaid rebate increases, drug manufacturers would […]
As the debate over prescription drug pricing heats up, I have been worried for a while that some of the federal policy solutions being considered in Congress and in the Administration could adversely affect Medicaid and its highly effective rebate program, whether inadvertently or intentionally. This could result in higher Medicaid drug costs, reduced beneficiary […]
Today, we issued our fifth issue brief in our Future of Children’s Health Coverage series. It focuses on how to build upon and improve the Medicaid Drug Rebate Program at both the federal and state levels in order to help state Medicaid programs better address their rising prescription drug costs. This, in turn, would ensure continued […]
Fifth in a series of briefs on the future of children’s health care coverage Introduction Prescription drugs are essential for the health of tens of millions of low-income children enrolled in Medicaid. They not only are part of routine pediatric care but also provide critical treatment and maintenance for chronic conditions such as asthma and […]
This webinar reviews overall drug pricing trends, current beneficiary access protections, effectiveness of Medicaid Drug Rebate Program, and state strategies to address rising Medicaid prescription drug costs while maintaining access to needed drugs.
On June 27, the Centers for Medicare and Medicaid Services partially approved Massachusetts’ Medicaid waiver proposal, but among other provisions, rejected a proposal to impose a “closed formulary” for prescription drugs under which the state could entirely exclude coverage of certain drugs in ways not permitted under current law. Instead, CMS expressed openness to approving […]
